(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 14.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Adaptive Biotechnologies's revenue in 2026 is $295,407,000.On average, 10 Wall Street analysts forecast ADPT's revenue for 2026 to be $47,726,838,138, with the lowest ADPT revenue forecast at $44,621,976,934, and the highest ADPT revenue forecast at $49,909,843,645. On average, 10 Wall Street analysts forecast ADPT's revenue for 2027 to be $58,331,379,552, with the lowest ADPT revenue forecast at $53,421,217,606, and the highest ADPT revenue forecast at $61,874,762,391.
In 2028, ADPT is forecast to generate $71,248,562,431 in revenue, with the lowest revenue forecast at $63,950,538,155 and the highest revenue forecast at $76,427,598,956.